Blockbuster drug with patent expiration in the next 10 years (12)-Disumab

Text | pick up shells

Amgen is no stranger to the costly patent cliff

In the absence of a large number of patent exclusivity losses in recent years, the company is expected to enter a growth phase driven by new drugs, including the migraine drug Aimovig (erenumab) and the newly approved anti-cancer drug Lumakras (sotorasib)

This situation may change at a later date, because the company's orthopedic drugs Prolia and Xgeva are expected to lose patent protection

Amgen’s annual report shows that denosumab’s patent is valid from 2021 to 2025

For Amgen, the loss of billions of dollars of exclusivity is a major event

Sales of Evenity ((romosozumab), a new osteoporosis drug launched in 2019, increased by 85% last year to 350 million U.

At the same time, in May of this year, Lumakras just received FDA approval for use in patients with KRAS G12C mutant non-small cell lung cancer

Attached table: Top 15 blockbuster drugs with patent expiration in the next 10 years